To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Parecoxib reduces pain and local inflammation factors 3 days after TKA

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
May 2014

Parecoxib reduces pain and local inflammation factors 3 days after TKA

Vol: 3| Issue: 5| Number:54| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Effect of perioperative parecoxib on postoperative pain and local inflammation factors PGE2 and IL-6 for total knee arthroplasty: a randomized, double-blind, placebo-controlled study

Eur J Orthop Surg Traumatol. 2014 Apr;24(3):395-401. doi: 10.1007/s00590-013-1203-4. Epub 2013 Mar 13.

Contributing Authors:
Y Zhu S Wang H Wu Y Wu

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

100 patients undergoing routine total knee arthroplasty were randomized to receive a parecoxib sodium analgesic regimen or placebo post-surgery, with the primary purpose of evaluating total morphine consumption during the first 24 hours postoperatively. Upon analysis, parecoxib sodium significantly reduced morphine consumption, pain at rest and during movement, and concentration of IL-6 and PGE-2 ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue